Covid-19 roundup: Sorrento threatens to sue critic of their coronavirus ‘cure’; Novavax signs with SK bioscience
Sorrento Therapeutics has come under fire for how they’ve characterized their Covid-19 research, taking heat in May from researchers, bio-ethicists and even some investors for claiming they had a Covid-19 “cure.” Now, Sorrento is threatening “legal action” against an investment research firm critical of its work.
Hindenburg Research first criticized the company for the “cure” claim in a lengthy report in May, and then on Tuesday, wrote on Twitter that CEO Henry Ji’s claims and CNBC coverage of a spit test Sorrento licensed from Columbia University had more than doubled its stock value. Hindenburg cited an unnamed Columbia official who called Sorrento’s claims “a complete joke.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,200+ biopharma pros reading Endpoints daily — and it's free.